Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies

Mark R. Stein, Robert P. Nelson, Joseph A. Church, Richard L. Wasserman, Michael Borte, Christiane Vermylen, Johann Bichler

Research output: Contribution to journalArticle

65 Scopus citations


Purpose: The present study was designed to evaluate the efficacy and safety of a novel, 10% liquid formulation of intravenous immunoglobulin, stabilized with 250 mmol/L l-proline (Privigen®), in patients with primary immunodeficiency disease. Materials and Methods: Eighty adults and children diagnosed with common variable immunodeficiency or X-linked agammaglobulinemia received intravenous Privigen® infusions (200-888 mg/kg) at 3- or 4-week intervals over a 12-month period, according to their previously established maintenance dose. The primary endpoint was the annual rate of acute serious bacterial infections. Results: There were six episodes of acute serious bacterial infections, corresponding to an annual rate of 0.08; the annual rate for all infections was 3.55. Mean serum IgG trough levels were between 8.84 and 10.27 g/L. A total of 1,038 infusions were administered, most of them at the maximum rate permitted (8.0 mg kg-1 min-1). Temporally associated adverse events, possibly or probably related to study drug, occurred in 9% of infusions, either during or within 72 h after infusion end. Conclusion: Privigen® is well tolerated and effective for the treatment of primary immunodeficiency.

Original languageEnglish (US)
Pages (from-to)137-144
Number of pages8
JournalJournal of Clinical Immunology
Issue number1
StatePublished - Jan 1 2009



  • Common variable immunodeficiency (CVID)
  • Intravenous immunoglobulin (IVIG)
  • Primary immunodeficiency (PID)
  • X-linked agammaglobulinemia (XLA)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this